Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
TNFRSF17 BCM, BCMA
Sequence Length (AA) Molecular Weight (Da)
184 20165
Protein Name
Tumor necrosis factor receptor superfamily member 17
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MLQMAGQCSQ NEYFDSLLHA CIPCQLRCSS NTPPLTCQRY CNASVTNSVK
60 70 80 90 100
GTNAILWTCL GLSLIISLAV FVLMFLLRKI NSEPLKDEFK NTGSGLLGMA
110 120 130 140 150
NIDLEKSRTG DEIILPRGLE YTVEECTCED CIKSKPKVDS DHCFPLPAME
160 170 180 184
EGATILVTTK TNDYCKSLPA ALSATEIEKS ISAR

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5934 Collapse assay details

Data source: Panorama

Official Gene Symbol
TNFRSF17
Peptide Sequence
SLPAALSATEIEK
Modification Type
unmodified
Protein - Site of Modification
167
Peptide - Site of Modification
N/A
Peptide Start
167
Peptide End
179
CPTAC ID
CPTAC-5934
Peptide Molecular Mass
1,328.7187
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b6 (1+) 42.4 30.4 12.5 43.5 30.9 19.8 60.7 43.3 23.4 15 27 15
b5 (1+) 103.9 27.5 21.7 98.8 30.4 25.6 143.4 41 33.6 15 27 15
y11 (2+) 19.9 9.4 6.2 27.5 14.4 10.1 33.9 17.2 11.9 15 27 15
y6 (1+) 60.6 30.7 14.6 82.2 31.4 13.6 102.1 43.9 20 15 27 15
y7 (1+) 57.8 19.3 6.1 46.1 22.5 10.7 73.9 29.6 12.3 15 27 15
y8 (1+) 69 21.4 17 75.5 24.4 22.6 102.3 32.5 28.3 15 27 15
y11 (1+) 48.5 18.3 12.3 54.6 20.8 13.4 73 27.7 18.2 15 27 15
sum 16.8 7.6 5.1 20.8 12.7 9.7 26.7 14.8 11 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5935 Collapse assay details

Data source: Panorama

Official Gene Symbol
TNFRSF17
Peptide Modified Sequence
SLPAALS[+79.966331]ATEIEK
Modification Type
Phospho (ST)
Protein - Site of Modification
174
Peptide - Site of Modification
7
Peptide Start
167
Peptide End
179
CPTAC ID
CPTAC-5935
Peptide Molecular Mass
1,408.6851
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b6 (1+) 51 21.5 16.8 65.6 25.5 16.2 83.1 33.4 23.3 15 27 15
y10 (2+) 27 18.5 16 31.1 20.6 20.1 41.2 27.7 25.7 15 27 15
y11 (2+) 18.2 9.4 3.4 18.7 9.9 12.7 26.1 13.7 13.1 15 27 15
y6 (1+) 50.1 26.6 23 57.3 19.9 27.1 76.1 33.2 35.5 15 27 15
y7 (1+) 40.5 26.5 17 32.3 29.3 24.3 51.8 39.5 29.7 15 27 15
y8 (1+) 55.6 19.1 20.9 61.9 21.7 21.4 83.2 28.9 29.9 15 27 15
y11 (1+) 48.8 15 14.1 45.9 16.9 18.6 67 22.6 23.3 15 27 15
sum 14 8.5 3.5 17.3 9.8 12 22.3 13 12.5 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5971 Collapse assay details

Data source: Panorama

Official Gene Symbol
TNFRSF17
Peptide Sequence
SLPAALSATEIEK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
4
Peptide Start
167
Peptide End
179
CPTAC ID
CPTAC-5971
Peptide Molecular Mass
1,328.7187
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
FFPE tumor tissue lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.Whiteaker JR, Lundeen RA, Zhao L, Schoenherr RM, Burian A, Huang D, Voytovich U, Wang T, Kennedy JJ, Ivey RG, Lin C, Murillo OD, Lorentzen TD, Thiagarajan M, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Reading JJ, Kaczmarczyk JA, Richardson CW, Garcia-Buntley SS, Bocik W, Hewitt SM, Murray KE, Do N, Brophy M, Wilz SW, Yu H, Ajjarapu S, Boja E, Hiltke T, Rodriguez H, Paulovich AG.Front Immunol. 2021 Nov 11;12:765898. doi: 10.3389/fimmu.2021.765898. eCollection 2021.PMID: 34858420


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTRAP 5500
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent nanoLC 425
Column Packing
3 µm ChromXP C18EP, 120 Å
Column Dimensions
150 x 0.3 mm
Flow Rate
0.3 µL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y11 (1+) 24.5 20.6 16.4 31.7 20.2 16.3 40.1 28.9 23.1 13 25 14
y8 (1+) 21.6 48.7 14.2 20.9 41.1 15.3 30.1 63.7 20.9 13 25 14
y7 (1+) 5.6 13.1 18.9 9.8 14 23.5 11.3 19.2 30.2 13 25 14
y11 (2+) 8.5 11.7 14.4 10.2 10.2 14.5 13.3 15.5 20.4 13 25 14
sum 7.9 10.3 11.2 8.1 10.1 12.4 11.3 14.4 16.7 13 25 14


Additional Resources and Comments


Assay Details for CPTAC-5972 Collapse assay details

Data source: Panorama

Official Gene Symbol
TNFRSF17
Peptide Modified Sequence
SLPAALS[+79.966331]ATEIEK
Modification Type
Phospho (S,T)
Protein - Site of Modification
N/A
Peptide - Site of Modification
4
Peptide Start
167
Peptide End
179
CPTAC ID
CPTAC-5972
Peptide Molecular Mass
1,408.6851
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
FFPE tumor tissue lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.Whiteaker JR, Lundeen RA, Zhao L, Schoenherr RM, Burian A, Huang D, Voytovich U, Wang T, Kennedy JJ, Ivey RG, Lin C, Murillo OD, Lorentzen TD, Thiagarajan M, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Reading JJ, Kaczmarczyk JA, Richardson CW, Garcia-Buntley SS, Bocik W, Hewitt SM, Murray KE, Do N, Brophy M, Wilz SW, Yu H, Ajjarapu S, Boja E, Hiltke T, Rodriguez H, Paulovich AG.Front Immunol. 2021 Nov 11;12:765898. doi: 10.3389/fimmu.2021.765898. eCollection 2021.PMID: 34858420


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTRAP 5500
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent nanoLC 425
Column Packing
3 µm ChromXP C18EP, 120 Å
Column Dimensions
150 x 0.3 mm
Flow Rate
0.3 µL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y10 (2+) 19.9 51.9 49.1 33.1 49.2 88.1 38.6 71.5 100.9 13 23 14
y11 (2+) 46.5 62.4 16.7 33.1 45.2 11.5 57.1 77.1 20.3 13 25 14
y7 (1+) 80.4 65.7 77.9 74.9 70.4 57.7 109.9 96.3 96.9 13 22 14
y11 (1+) 46.1 76.3 53.9 88.8 59.1 43.1 100.1 96.5 69 7 24 14
sum 10.8 18.2 14.2 8.5 17.6 9.9 13.7 25.3 17.3 13 25 14


Additional Resources and Comments